HRTX
Heron Therapeutics Inc

7,328
Mkt Cap
$146.8M
Volume
2.04M
52W High
$2.61
52W Low
$0.765
PE Ratio
-6.46
HRTX Fundamentals
Price
$0.7786
Prev Close
$0.8173
Open
$0.82
50D MA
$1.20
Beta
1.43
Avg. Volume
1.75M
EPS (Annual)
-$0.1211
P/B
11.04
Rev/Employee
$1.21M
$311.78
Loading...
Loading...
News
all
press releases
Baker BROS. Advisors LP Purchases New Position in Heron Therapeutics, Inc. $HRTX
Baker BROS. Advisors LP purchased a new stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Citigroup Inc. Increases Stock Position in Heron Therapeutics, Inc. $HRTX
Citigroup Inc. boosted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 4,666.9% during the third quarter, according to the company in its most recent filing with the...
MarketBeat·15d ago
News Placeholder
HC Wainwright Has Negative Forecast for HRTX FY2026 Earnings
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Heron Therapeutics in a research note...
MarketBeat·19d ago
News Placeholder
What is Northland Securities' Forecast for HRTX Q1 Earnings?
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for Heron Therapeutics in a research report issued on Thursday...
MarketBeat·19d ago
News Placeholder
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to Strong Sell at Zacks Research
Zacks Research lowered Heron Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Thursday...
MarketBeat·21d ago
News Placeholder
What is HC Wainwright's Estimate for HRTX Q1 Earnings?
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Heron Therapeutics in a research report issued to clients...
MarketBeat·22d ago
News Placeholder
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Estimates By $0.01 EPS
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate...
MarketBeat·22d ago
News Placeholder
Heron Therapeutics Q4 Earnings Call Highlights
Heron Therapeutics (NASDAQ:HRTX) reported fourth-quarter and full-year 2025 results while outlining plans to increase commercial investment in 2026 to build on what management described as an...
MarketBeat·22d ago
News Placeholder
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·22d ago
News Placeholder
Earnings Breakdown: Heron Therapeutics Q4
read more...
Benzinga·23d ago
<
1
2
...
>

Latest HRTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.